PFO
ALDR

Pathstone Family Office’s Alder Biopharmaceuticals ALDR Stock Holding History

Pathstone Family Office’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-42
Closed -$1K – 984
2019
Q1 		$1K Hold
42
– – ﹤0.01% 875
2018
Q4 		$0 Buy
+42
New +$538 ﹤0.01% 580

Other funds holding ALDR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pathstone Family Office's ALDR Position: Q2 2019 in Review

Pathstone Family Office sold out of Alder Biopharmaceuticals (ALDR) in Q2 2019, closing a stake of 42 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in ALDR in Q4 2018 and held it in 2 quarters. The position peaked at $1K in Q1 2019. 127 funds tracked by Wall St. Rank hold ALDR as of Q2 2019.

  • Pathstone Family Office reported no remaining Alder Biopharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Pathstone Family Office sold 42 Alder Biopharmaceuticals shares in Q2 2019, an estimated $1K.
  • Pathstone Family Office first reported a position in Alder Biopharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Pathstone Family Office's Alder Biopharmaceuticals position peaked at $1K in Q1 2019.
  • 127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2019.

Based on Pathstone Family Office's 13F filing for Q2 2019, filed 14 Aug 2019.